SMS Pharmaceuticals Q2 FY27 Results and Key Leadership Changes
SMS Pharmaceuticals Ltd · Change in Management · 04 Nov 2026, 7:01 pm
SMS Pharmaceuticals Q2 FY27 Results and Key Leadership Changes SMS Pharmaceuticals reported a 30.38% YoY increase in consolidated revenue from operations to ₹31,608.93 lakhs for the quarter ended 30th Sep'26, compared to ₹24,242.95 lakhs in the previous year. Consolidated net profit rose 57.44% YoY to ₹3,985.25 lakhs from ₹2,531.27 lakhs, with basic EPS rising to ₹4.26 from ₹2.84. Separately, the Board approved the resignation of Company Secretary Thirumalesh Tumma, effective 4th Nov'26, and appointed Manohar Mollama as Company Secretary and Compliance Officer effective 5th Nov'26.
Original exchange filing (PDF)
More announcements from SMS Pharmaceuticals Ltd
- Earnings Call Transcript · 10 Nov 2026
- Investors Meet Audio Recording · 05 Nov 2026
- Press release on Financial Results · 05 Nov 2026
- Investor Presentation for quarter and half year ended September 30, 2026 · 04 Nov 2026
- Financial results and change in Company Secretary · 04 Nov 2026
- SMS Pharmaceuticals Limited has informed the Exchange about General Updates · 04 Nov 2026
- SMS Pharmaceuticals Limited has informed the Exchange about Change in Company Secretary/Compliance Officer · 04 Nov 2026
- Outcome of Board Meeting and Financial Results · 04 Nov 2026
